Evidence-based treatment guidelines for HCV infection from the expert panel of the AASLD and IDSA.
Guidelines for hepatitis B virus (HBV) screening among patients with cancer have been updated.
Recent results on entecavir may change use of lamivudine prophylaxis in cancer patients with the hepatitis B virus.
Risk of hepatitis B virus (HBV) related hepatitis and HBV reactivation is lower with entecavir and lamivudine in lymphoma.
To prevent reactivation, antiviral therapy recommended for chemotherapy, immunotherapy patients who are hepatitis B positive.
Immunotherapy targeting the CLTA4 protein in HCV-related HCC demonstrated modest extended survival in a disease that has a high mortality rate.